4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 99 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,858,938 | -41.0% | 1,717,120 | -16.3% | 0.00% | -50.0% |
| Q2 2023 | $37,051,270 | +5.5% | 2,050,430 | +0.4% | 0.00% | 0.0% |
| Q1 2023 | $35,105,229 | -36.0% | 2,042,189 | -17.3% | 0.00% | 0.0% |
| Q4 2022 | $54,865,718 | +907.8% | 2,470,316 | +264.8% | 0.00% | – |
| Q3 2022 | $5,444,000 | +23.3% | 677,176 | +7.1% | 0.00% | – |
| Q2 2022 | $4,415,000 | -80.4% | 632,525 | -57.5% | 0.00% | -100.0% |
| Q1 2022 | $22,519,000 | -18.5% | 1,489,371 | +18.2% | 0.00% | 0.0% |
| Q4 2021 | $27,637,000 | +220.6% | 1,259,660 | +294.1% | 0.00% | – |
| Q3 2021 | $8,621,000 | +116.3% | 319,662 | +93.2% | 0.00% | – |
| Q2 2021 | $3,985,000 | -14.0% | 165,492 | +54.9% | 0.00% | – |
| Q1 2021 | $4,634,000 | – | 106,833 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
| Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
| BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
| Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
| Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
| Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
| Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
| Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |